Enzyme-linked immunosorbent assay (ELISA) is widely used to detect and quantify antibodies in immunological research. However, selecting an appropriate assay kit becomes more complex when the target is a non-IgG antibody suchRead More…
Pharmacokinetic and pharmacodynamic studies are often summarized with a familiar set of measurements: maximum serum concentration, exposure, terminal half-life, and a downstream efficacy marker. For many non-IgG therapeutics, however, those measurements describeRead More…
Antibody characterization is often described as a collection of analytical tests. For non-IgG antibodies, however, it is more useful to think of characterization as a decision-making framework. IgA, IgM, IgE, IgY, andRead More…
Introduction: Moving Beyond the IgG-Centered Bioprocessing Model For decades, antibody production has been largely shaped by the success of IgG monoclonal antibodies. Most expression platforms, purification workflows, analytical assays, and scale-up strategiesRead More…
Non-IgG antibodies are gaining increasing attention in therapeutic discovery and biotechnological research because they offer structural flexibility, compact molecular size, modular design potential, and unique biological advantages that conventional IgG antibodies mayRead More…
For decades, the therapeutic antibody landscape has been heavily dominated by the Immunoglobulin G (IgG) isotype. Its long serum half-life, well-understood pharmacokinetics, and manageable structural properties have made it the gold standardRead More…
The landscape of therapeutic antibodies is rapidly evolving. For decades, the biopharmaceutical industry has heavily relied on the standard Immunoglobulin G (IgG) framework to develop life-saving treatments for oncology, autoimmune diseases, andRead More…
For decades, the biopharmaceutical landscape has been dominated by Immunoglobulin G (IgG). Its favorable half-life, well-understood structure, and established manufacturing processes have made it the gold standard for monoclonal antibody (mAb) therapeutics. However,Read More…
Non-IgG antibodies—especially IgA, IgM, and IgE—are re-entering biologics pipelines for reasons IgG cannot always match: mucosal targeting, high avidity through multivalency, and specialized effector biology. But the same structural features that makeRead More…
IgG has been the “default chassis” for therapeutic antibodies for decades—and for good reason: mature discovery workflows, predictable developability, well-characterized Fc effector biology, and scalable manufacturing. But the industry’s IgG-centric comfort zoneRead More…